Valuation dashboard for Vyome Holdings, Inc. (HIND) with P/E N/A, P/B 2.32, EV/EBITDA -0.67 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Analysis Summary
Vyome Holdings, Inc. reported revenue of $319714 in the most recent fiscal year, growing at a 5-year CAGR of -51.0%.
Trailing-twelve-month margins: gross margin 46.5%, operating margin -32.5%, net margin -87.2%.
At the current price of $1.96, HIND has negative trailing earnings (P/E not meaningful) and an ROE of -254.62%. Market capitalisation stands at $14M.
Balance sheet quality for HIND: current ratio of 2.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.32 |
| EV / EBITDA | -0.67 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $1.86 |
| vs Current Price | -5.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| HIND | Vyome Holdings, Inc. | $14M | 2.32 | -254.6% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.3B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $131.0B | 29.86 | 6.49 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.6B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $81.3B | 19.15 | 2.61 | 13.8% |
| MRNA | Moderna, Inc. | $62.7B | 1.46 | -39.2% | |
| ARGX | argenx SE | $61.9B | 36.71 | 7.48 | 21.7% |
| RVMD | Revolution Medicines, Inc. | $41.9B | 16.04 | -96.4% |
Price
| Price | $1.96 |
| Market Cap | $14M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -254.62% |
| Return on Invested Capital | -57.53% |
| Return on Assets | -123.23% |
| Gross Margin | 46.50% |
| Operating Margin | -3250.25% |
| Net Margin | -8716.77% |
Related companies: ARMP · CCCC · CDXS · CGEN · IMDX · IPHA · NVCT
Explore sector: Healthcare · Biotechnology
More sections of HIND: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks